Grants and Contracts Details
Description
Vivoryon Therapeutics [Vivoryon] has developed a novel drug candidate, varoglutamstat (PQ912), for
the potential treatment of early AD. Varoglutamstat is a first-in-class, highly specific and potent small
molecule with a unique mechanism of action. In preclinical models, these toxic effects can be
attenuated with varoglutamstat treatment. This clinical study targets early AD with the goal of
improving cognition and everyday function and attenuating longer term disease progression through its
dual pathways of varoglutamstat’s mode of action.
Status | Active |
---|---|
Effective start/end date | 10/1/22 → 2/28/25 |
Funding
- University of California San Diego Health: $66,826.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.